Table 2.
Patients characteristics in Study C.
| Variables | N = 7 |
|---|---|
| Age, years | 72.7 ± 2.2 |
| Sex, male | 7 (100) |
| Body Mass Index, kg/m2 | 24.2 ± 0.6 |
| Blood pressure, mmHg | |
| Systolic | 130.6 ± 3.0 |
| Diastolic | 65.4 ± 3.0 |
| Comorbidities | |
| Diabetes mellitus | 6 (86) |
| Hypertension | 7 (100) |
| Dyslipidemia | 6 (86) |
| Medication | |
| β-blocker | 4 (57) |
| ACE-I/ARB | 6 (86) |
| Calcium channel blocker | 4 (57) |
| Antiplatelet | 7 (100) |
| PPI/H2 blocker | 7 (100) |
| Statin | 5 (71) |
| Laboratory data | |
| Aspartate transaminase, U/L | 27.0 ± 2.4 |
| Alanine transaminase, U/L | 24.7 ± 5.5 |
| Blood urea nitrogen, mg/dL | 18.2 ± 1.5 |
| Creatinine, mg/dL | 0.92 ± 0.04 |
| Glycohemoglobin, % | 6.5 ± 0.2 |
| C-reactive protein, mg/dL | 0.21 ± 0.05 |
| Total cholesterol, mg/dL | 161.0 ± 18.9 |
| HDL-C, mg/dL | 46.7 ± 5.4 |
| LDL-C, mg/dL | 91.4 ± 14.1 |
| Triglycerides, mg/dL | 144.7 ± 30.4 |
Data are shown as mean ± standard error of the mean or n (%).
ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; PPI proton pump inhibitor.